Company intelligence / Profile preview

Xinjingzhiyuan Biotechnology (Suzhou) Co., Ltd.

Suzhou, Jiangsu Sheng, Chinaneowisebio.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of autologous TCR-T cell therapy in subjects with advanced solid tumors, specifically targeting KRAS G12V/G12D mutations.

Therapeutic areas: Oncology
Modalities: TCR therapy
Industry: Biotech

Partnerships

Wuhan Xiehe Hospital Tower

Beyond the preview

Go deeper on Xinjingzhiyuan Biotechnology (Suzhou) Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xinjingzhiyuan Biotechnology (Suzhou) Co., Ltd..